, Oregon Medical Research Center, Portland, OR
-
SKIN The Journal of Cutaneous Medicine Vol. 4 No. 6 (2020): November Issue & Poster Presentations (FC20 Dermatology Conference®) - Poster Presentations from FC20 Clinical Dermatology Conference®: Psoriasis
Durability of DLQI Improvements Among Patients with Moderate to Severe Plaque Psoriasis Treated with Certolizumab Pegol: Three-Year Results from Two Phase 3 Trials (CIMPASI-1 and CIMPASI-2)
Abstract
Poster PDF
-
SKIN The Journal of Cutaneous Medicine Vol. 4 No. 6 (2020): November Issue & Poster Presentations (FC20 Dermatology Conference®) - Poster Presentations from FC20 Clinical Dermatology Conference®: Psoriasis
Dose Adjustment Patterns in the Open-Label Extension Arms of Three Phase 3 Trials of Certolizumab Pegol in Psoriasis: CIMPASI-1, CIMPASI-2, and CIMPACT
Abstract
Poster PDF
-
SKIN The Journal of Cutaneous Medicine Vol. 5 No. 1 (2021): January Issue & Poster Presentations (WC21 Dermatology Conference®) - Poster Presentations from FC23 Dermatology Conference®: Psoriasis
Durability of DLQI Improvements Among Patients with Moderate to Severe Plaque Psoriasis Treated with Certolizumab Pegol: Three-Year Results from Two Phase 3 Trials (CIMPASI-1 and CIMPASI-2)
Abstract
Poster PDF
-
SKIN The Journal of Cutaneous Medicine Vol. 3 (2019): Supplemental Issue: Scientific Posters Presented at 2019 Fall Clinical Dermatology Conference®-Las Vegas - Poster Presentations from FC23 Dermatology Conference®: Psoriasis
Long-term Efficacy and Safety of Brodalumab in Patients With Psoriasis Disease Duration <10 and ≥10 Years: Analysis of Two Phase 3 Studies
Abstract
Poster PDF
-
SKIN The Journal of Cutaneous Medicine Vol. 4 No. 1 (2020): January Issue & Poster Presentations (2020 Winter Clinical Dermatology Conference®) - Poster Presentations at 2020 Winter Clinical Dermatology Conference®: Psoriasis
Long-Term Safety of Certolizumab Pegol in Plaque Psoriasis: Pooled Analysis over 3 Years from Three Phase 3, Randomized, Placebo-Controlled Studies
Abstract
Poster PDF
-
SKIN The Journal of Cutaneous Medicine Vol. 4 No. 6 (2020): November Issue & Poster Presentations (FC20 Dermatology Conference®) - Atopic Dermatitis
Impact of Lebrikizumab on Patient-Reported Outcomes in Atopic Dermatitis: Prospective and Post Hoc Analyses of a Phase 2b Clinical Trial Demonstrate Clinically Meaningful Improvements
Abstract
Poster PDF
-
SKIN The Journal of Cutaneous Medicine Vol. 4 No. 6 (2020): November Issue & Poster Presentations (FC20 Dermatology Conference®) - Poster Presentations from FC20 Clinical Dermatology Conference®: Psoriasis
Deucravacitinib (BMS-986165), an Oral, Allosteric Tyrosine Kinase 2 Inhibitor, Reduces Body Surface Area Involvement and Improves Quality of Life in Patients With Psoriasis
Abstract
Poster PDF
-
SKIN The Journal of Cutaneous Medicine Vol. 4 No. 6 (2020): November Issue & Poster Presentations (FC20 Dermatology Conference®) - Poster Presentations from FC20 Clinical Dermatology Conference®: Psoriasis
Reductions in Absolute PASI Over 144 Weeks of Treatment with Certolizumab Pegol in Patients with Plaque Psoriasis: Pooled Analysis from Two Phase 3 Trials (CIMPASI-1 and CIMPASI-2)
Abstract
Poster PDF
-
SKIN The Journal of Cutaneous Medicine Vol. 3 (2019): Supplemental Issue: Scientific Posters Presented at 2019 Fall Clinical Dermatology Conference®-Las Vegas - Poster Presentations from FC23 Dermatology Conference®: Psoriasis
Importance of Complete Skin Clearance on Quality of Life: Analysis of Three Phase 3 Studies of Brodalumab
Abstract
Poster PDF
-
SKIN The Journal of Cutaneous Medicine Vol. 3 (2019): Supplemental Issue: Scientific Posters Presented at 2019 Fall Clinical Dermatology Conference®-Las Vegas - Eczema & Xerosis
Lebrikizumab, a High-Affinity IL-13 Inhibitor, Improves Clinical Manifestations in Moderate-to-Severe Atopic Dermatitis: Primary Results From a Randomized, Double-Blinded, Placebo-Controlled, Dose-Ranging, Phase 2b Study
Abstract
Poster PDF
-
SKIN The Journal of Cutaneous Medicine Vol. 4 No. 6 (2020): November Issue & Poster Presentations (FC20 Dermatology Conference®) - Poster Presentations from FC20 Clinical Dermatology Conference®: Psoriasis
Efficacy and Safety of Bimekizumab in Patients with Moderate to Severe Plaque Psoriasis: Results from BE VIVID, a 52-Week Phase 3, Randomized, Double-Blinded, Ustekinumab- and Placebo-Controlled Study
Abstract
Poster PDF
-
SKIN The Journal of Cutaneous Medicine Vol. 4 No. 6 (2020): November Issue & Poster Presentations (FC20 Dermatology Conference®) - Poster Presentations from FC20 Clinical Dermatology Conference®: Psoriasis
Durable Efficacy of Certolizumab Pegol Dosed at 400 mg Every Two Weeks Over 128 Weeks in Patients with Plaque Psoriasis Enrolled in Three Phase 3 Trials (CIMPASI-1, CIMPASI-2, and CIMPACT)
Abstract
Poster PDF
-
SKIN The Journal of Cutaneous Medicine Vol. 4 No. 6 (2020): November Issue & Poster Presentations (FC20 Dermatology Conference®) - Poster Presentations from FC20 Clinical Dermatology Conference®: Psoriasis
Efficacy and Safety of Bimekizumab in Patients with Moderate to Severe Plaque Psoriasis: Results from BE READY, a 56-Week Phase 3, Randomized, Double-Blinded, Placebo-Controlled Study with Randomized Withdrawal
Abstract
Poster PDF
-
SKIN The Journal of Cutaneous Medicine Vol. 7 No. 6 (2023): November 2023 Issue - Poster Presentations from FC23 Dermatology Conference®: Psoriasis
6-Month Real World Study to Assess the Effectiveness of Ixekizumab After Switching from IL-23 Inhibitors and Other Biologic Therapies: The CorEvitas Psoriasis Registry
Details
PDF